Clinical Trial Update: Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating the safety and efficacy of CP-316,311 for Major depressive disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CP-316,311

Snippet

Sponsor: Pfizer | Conditions: Depressive Disorder, Major | Phase 2 | Status: TERMINATED